6 julio 2015
In patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life, research shows. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/3QGnhA1dZvw/150706114233.htm
